Genentech, a biotechnology company owned by Roche Pharmaceuticals, has announced promising results from a phase III clinical trial of experimental therapy ocrelizumab in people with primary progressive MS.
In a press release from the company, researchers report that ocrelizumab treatment was found to significantly reduce clinical disability progression in comparison to a placebo.
Ocrelizumab is a humanised monoclonal antibody, which is related to the mouse antibody known as rituximab that is sometimes used to treat MS and the related disorder neuromyelitis optica. The treatment is given as an infusion every six months.
Although these initial results are promising the full trial results are still yet to be published which will help us to better understand the risks and potential benefits of ocrelizumab as a treatment for primary progressive MS.
For further information on this study and treatment, visit Multiple Sclerosis Research Australia.